跳至主要内容
临床试验/NCT01332383
NCT01332383已完成不适用

Special Drug Use Investigation for AMERGE Tablet (Long-term)

GlaxoSmithKline0 个研究点目标入组 300 人开始时间: 2009年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
300
主要终点
The number of adverse drug reactions and serious adverse events

研究概览

简要总结

To investigate the long-term safety and efficacy of AMERGE (naratriptan hydrochloride) on Japanese patients with migraine headache in clinical setting

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Must use AMERGE for the first time

排除标准

  • Patients with hypersensitivity to naratriptan or any of the components.
  • Patients with history, symptoms, or signs of myocardial infarction, ischemic cardiac or angina inversa
  • Patients with history of cerebral vascular disturbance or transient ischaemic attack
  • Patients with peripheral vascular syndromes
  • Patients with uncontrolled hypertension
  • Patients with severe renal or hepatic impairment
  • Patients using treatment with another 5-HT1 agonist, an ergotamine-containing or ergot-type medication

研究组 & 干预措施

Patients prescribed AMERGE

Patients with migraine disorders prescribed AMERGE during study period

干预措施: Naratriptan (Drug)

结局指标

主要结局

The number of adverse drug reactions and serious adverse events

时间窗: 6 months

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验